Top news of the week: 01.04.2021.
Companies And Industries
2021 Biopharma Update on the Novel Coronavirus: March 30
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2021.
Orphazyme shares sink as late-stage test of 'heat shock protein' flops
Orphazyme saw its stock sink more than 30% in Europe Monday morning after it failed to to hit any of the endpoints in a phase 2/3 trial.
Biogen's Aducanumab: A Look at the Drug’s History and Recent Updates
One of the big drugs investors, analysts and pretty much everyone else in the biopharma industry is keeping an eye on is Biogen and Eisai’s aducanumab for Alzheimer’s disease.
BioSpace Movers & Shakers, March 26
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Three Biopharma Companies Making Their Nasdaq Debut
This morning, Ikena Oncology, Design Therapeutics and Edgewise Therapeutics began trading on the exchange.
Innate Immunity: French Biotech Builds Antibody Pipeline against Cancer
Innate Pharma chairman and CEO Mondher Mahjoubi, MD, tells GEN Edge that his company's top priority is the development of lacutamab, as it builds out a pipeline of antibodies against cancer.
Moderna CEO Bancel snags close to $13M in 2020 pay, thanks to COVID-19 vaccine work
For his work putting mRNA in the headlines—and a COVID-19 shot on the market—Moderna CEO Stéphane Bancel snared a pay package worth $12.85 million for 2020. That's a hefty increase from ...
British T-cell cancer biotech Achilles Therapeutics guns for $176M IPO
Achilles Therapeutics is looking for a meaty $176 million initial public offering for its next-gen immuno-oncology work.